Miranda Jayne Toledano - Dec 22, 2023 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role
Chief Executive Officer, Director
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Stock symbol
ENTX
Transactions as of
Dec 22, 2023
Transactions value $
$20,000
Form type
4
Date filed
12/27/2023, 08:27 AM
Previous filing
Sep 14, 2023
Next filing
Jul 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTX Ordinary Shares, par value NIS 0.0000769 per share Purchase $17K +24K +27.59% $0.71 111K Dec 22, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTX Warrants (right to buy) Purchase $2.99K +24K $0.13* 24K Dec 22, 2023 Ordinary Shares, par value NIS 0.0000769 per share 24K $1.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules.